J Clin Endocrinol Metab. 2021;106(3):724-735.
Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma.
제1저자 문재훈, 류창환 · 교신저자 박영주, 이은경
소속 (13)
- Department of Internal Medicine, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Republic of Korea.
- Department of Otorhinolaryngology, National Cancer Center, Goyang, Republic of Korea.
- Center for Thyroid Cancer, National Cancer Center, Goyang, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.
- Department of Surgery, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Republic of Korea.
- Department of Otorhinolaryngology, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea.
- Department of Otorhinolaryngology, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Republic of Korea.
- Department of Radiology, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.
- Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea.
- Department of Radiology, Seoul National University Bundang Hospital and College of Medicine, Seongnam, Republic of Korea.
- Department of Radiology, National Cancer Center, Goyang, Republic of Korea.
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Abstract
CONTEXT The long-term quality of life (QoL) in patients with low-risk papillary thyroid microcarcinoma (PTMC) underwent active surveillance (AS) and immediate surgery is unclear.
OBJECTIVE The aim of this study was to investigate the effect of initial treatment choice on 2-year QoL in patients with low-risk PTMC.
DESIGN, SETTING, AND PARTICIPANTS We analyzed 2652 QoL surveys from 1055 subjects enrolled in ongoing multicenter prospective cohort study on active surveillance of PTMC, in which the median follow-up duration was 24.4 months.
MAJOR OUTCOME MEASURE We evaluated QoL of patients with low-risk PTMC according to their treatment modality using generalized estimating equation.
RESULTS Six hundred and seventy-four subjects (male = 161; mean age = 48.8 ± 11.9 years) with low-risk PTMC chose AS while 381 subjects (male = 75; mean age = 45.7 ± 10.4 years) chose immediate surgery, including lobectomy/isthmusectomy (L/I) and total thyroidectomy (TT). Among the 817 subjects who completed baseline QoL surveys, 2-year QoL was good in order of AS (n = 500), L/I (n = 238), and TT (n = 79) groups after adjustment for age, sex, baseline tumor size, and baseline QoL scores. Among the 101 subjects who changed their treatment from AS to surgery during the follow-up period, 35 subjects who changed treatment due to disease progression had better QoL than 66 subjects who had no disease progression.
CONCLUSIONS This study identified QoL as a major issue in choosing an initial treatment of low-risk PTMC and highlighted the possibility of using AS as the primary treatment.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Keywords
Immediate surgeryactive surveillancepapillary thyroid microcarcinomaquality of life
그 밖의 정보
- 출판 형태
- Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- 저널
- The Journal of clinical endocrinology and metabolism · eISSN 1945-7197
- MeSH
- Adult · Carcinoma, Papillary / epidemiology / pathology / therapy · Choice Behavior / physiology · Cohort Studies · Disease Progression · Female · Follow-Up Studies · Humans · Longitudinal Studies · Male · Middle Aged · Quality of Life* · Republic of Korea / epidemiology · Thyroid Neoplasms / epidemiology / pathology / therapy · Watchful Waiting / statistics & numerical data
- 데이터
- ClinicalTrials.gov: NCT02938702